Allogene Therapeutics, Inc. (ALLO) Income Statement
ALLO 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsALLO revenue and net income
ALLO profit margins
ALLO growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −100.0% | — | — | — |
| Gross profit | −56,277.3% | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
ALLO quarterly EPS vs estimates
Allogene Therapeutics beat the analyst EPS estimate in 8 of the last 8 quarters. Next report: November 5, 2026 (estimate $-0.13).
ALLO income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $22,000 | $95,000 | $243,000 | $38.5M | $38.3M | $0 | $0 | $0 |
| Cost of revenue | $12.4M | $13.6M | $14.2M | $16.7M | $13.1M | $11.5M | $5.0M | $1.5M | $0 |
| Gross profit | −$12.4M | $22,000 | $95,000 | $243,000 | $38.5M | −$11.5M | −$5.0M | −$1.5M | $0 |
| Research & development | $150.2M | $192.3M | $242.9M | $256.4M | $220.2M | $193.0M | $144.5M | $151.9M | $151.9M |
| Sales, general & admin | $56.8M | $65.2M | $71.7M | $79.3M | $74.1M | $65.3M | $57.5M | $41.0M | $24,000 |
| Total operating expenses | $194.6M | $273.2M | $327.8M | $335.7M | $294.3M | $258.2M | $202.0M | $192.8M | $2,000 |
| Operating income | −$206.9M | −$273.2M | −$327.7M | −$335.4M | −$255.8M | −$258.2M | −$202.0M | −$192.8M | −$2,000 |
| Interest income | $19.3M | $20.2M | $14.8M | $4.6M | $1.7M | $9.2M | $17.4M | $5.8M | — |
| Interest expense | $1.1M | $181,000 | $17.1M | $17.1M | $10.5M | $9.2M | $5.0M | $3.4M | $0 |
| Income before taxes | −$190.9M | −$257.1M | −$327.3M | −$332.6M | −$257.0M | −$250.2M | −$184.9M | −$211.6M | −$24,000 |
| Income taxes | — | $443,000 | −$2.8M | −$2.8M | −$12.2M | −$16.8M | −$331,000 | −$117,000 | −$24,000 |
| Net income | −$190.9M | −$257.6M | −$327.3M | −$329.8M | −$244.8M | −$233.5M | −$184.6M | −$211.5M | −$2,000 |
| EBITDA | −$177.5M | −$243.3M | −$313.1M | −$321.2M | −$245.3M | −$250.7M | −$179.9M | −$206.8M | $22,000 |
| EPS (diluted) | −$0.86 | −$1.25 | −$2.01 | −$2.32 | −$1.89 | −$2.08 | −$1.81 | −$3.03 | $0.00 |
| Gross margin | — | 100.0% | 100.0% | 100.0% | 100.0% | −30.1% | — | — | — |
| Operating margin | — | −1,241,813.6% | −344,986.3% | −138,044.9% | −664.6% | −673.5% | — | — | — |
| Net margin | — | −1,170,863.6% | −344,489.5% | −135,726.3% | −636.1% | −608.9% | — | — | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.6M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $22,000 | $0 | $22,000 |
| Cost of revenue | $0 | $2.9M | $3.1M | $31.2M | $40.2M | $3.1M | $3.2M | $44.7M | $50.4M | $3.6M | $3.5M | $3.6M |
| Gross profit | $4.6M | −$2.9M | −$3.1M | −$31.2M | −$40.2M | −$3.1M | −$3.2M | −$44.7M | −$50.4M | −$3.5M | −$44,000 | −$3.5M |
| Research & development | $30.7M | $32.0M | $28.6M | $31.2M | $40.2M | $50.2M | $45.0M | $44.7M | $50.4M | $52.3M | $54.7M | $46.0M |
| Sales, general & admin | $20.8M | $14.1M | $13.8M | $13.7M | $14.3M | $15.0M | $15.5M | $16.3M | $16.1M | $17.3M | $17.2M | $17.0M |
| Total operating expenses | $51.6M | $46.1M | $42.4M | $44.9M | $56.8M | $65.2M | $60.5M | $71.8M | $71.4M | $66.0M | $85.1M | $59.4M |
| Operating income | −$46.9M | −$46.1M | −$42.4M | −$44.9M | −$56.8M | −$65.2M | −$60.5M | −$71.8M | −$71.4M | −$69.5M | −$85.2M | −$63.0M |
| Interest income | $4.6M | $3.6M | $3.7M | $3.9M | $6.2M | $5.5M | $3.0M | $6.7M | $5.0M | $5.4M | $6.3M | $6.2M |
| Interest expense | $343,000 | $300,000 | $313,000 | $344,000 | $268,000 | $150,000 | $81,000 | $100,000 | $0 | $0 | $366,000 | $0 |
| Income before taxes | −$42.7M | −$42.6M | −$38.8M | −$41.4M | −$50.9M | −$59.7M | −$59.5M | −$66.3M | −$66.4M | −$65.0M | −$89.3M | −$62.3M |
| Income taxes | — | — | — | — | — | — | $443,000 | — | −$1 | $3.5M | −$65,000 | −$6.2M |
| Net income | −$42.7M | −$42.6M | −$38.8M | −$41.4M | −$50.9M | −$59.7M | −$59.9M | −$66.3M | −$66.4M | −$65.0M | −$89.3M | −$62.3M |
| EBITDA | −$39.7M | −$39.4M | −$35.4M | −$38.0M | −$47.6M | −$56.5M | −$56.2M | −$63.0M | −$62.7M | −$61.4M | −$68.5M | −$58.7M |
| EPS (diluted) | −$0.13 | −$0.18 | −$0.17 | −$0.19 | −$0.22 | −$0.28 | −$0.28 | −$0.27 | −$0.32 | −$0.38 | −$0.43 | −$0.37 |
| Gross margin | 100.0% | — | — | — | — | — | — | — | — | −16,059.1% | — | −16,136.4% |
| Operating margin | −1,011.2% | — | — | — | — | — | — | — | — | −315,927.3% | — | −286,345.5% |
| Net margin | −919.8% | — | — | — | — | — | — | — | — | −295,454.5% | — | −283,122.7% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in ALLO's financial statements (latest annual report filed March 12, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
ALLO financial results
Allogene Therapeutics reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $190.9 million. Diluted earnings per share came to −$0.86.
See the ALLO stock overview for the latest quote and news, or the ALLO chart for price history and technical indicators.
ALLO income statement FAQ
Does Allogene Therapeutics have revenue?
Allogene Therapeutics reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Allogene Therapeutics profitable?
No. Allogene Therapeutics reported a net loss of $190.9 million in fiscal 2025.
How much does Allogene Therapeutics spend on research and development?
Allogene Therapeutics spent $150.2 million on research and development in fiscal 2025.
What are Allogene Therapeutics's earnings per share?
Allogene Therapeutics earned $-0.86 per diluted share in fiscal 2025, compared with $-1.25 a year earlier.
When will Allogene Therapeutics report its next earnings?
Allogene Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 after the market closes.
When does Allogene Therapeutics's fiscal year end?
Allogene Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 12, 2026.